

AMENDMENTS TO THE CLAIMS

1. (original) A method for identifying a test agent as reducing apoptosis of a macrophage cell comprising:

- (a) providing:
 - (i) macrophage cells; and
 - (ii) a test agent; and
- (b) contacting said macrophage cells in the presence of said test agent to produce contacted macrophage cells and in the absence of said test agent to produce control cells; and
- (c) detecting reduced activity of Protein Kinase R in said treated cells compared to Protein Kinase R in said control cells, wherein said detecting identifies said test agent as reducing apoptosis of macrophage cells.

2. (canceled).

3. (currently amended) The ~~methods~~ method of Claim 1 ~~and Claim 2~~ further comprising, d) identifying said test agent as anti-bacterial.

4. (canceled).

5. (canceled).

6. (original) A method for reducing apoptosis of macrophage cells, comprising:

- (a) providing:
 - (i) macrophage cells; and
 - (ii) an agent that reduces activity of Protein Kinase R; and
- (b) contacting said macrophage cells with said agent under conditions such that said agent reduces activity of said Protein Kinase R.

7. (canceled).

8. (original) The method of Claim 6, wherein said macrophage cells are contacted with a molecule chosen from one or more of lipopolysaccharide, lipoteichoic acid, *Yersinia pseudotuberculosis* YopJ protein, and protein expressed by the *Salmonella typhimurium* SPI2 locus.

9. (original) The method of Claim 6, wherein said macrophage cells are contacted with a bacterium.

10. (original) The method of Claim 9, wherein said bacterium is gram-negative.

11. (original) The method of Claim 10, wherein said gram-negative bacterium is one or more of *Yersinia species*, *Salmonella typhimurium*, and *H. influenza*.

12. (original) The method of Claim 9, wherein said bacterium is gram-positive.

13. (original) The method of Claim 12, wherein said gram-positive bacterium is a *B. anthracis*.

14. (original) The method of Claim 6, wherein said macrophage cells are contacted with one or more of dsRNA and virus prior to contacting with a molecule chosen from one or more of lipopolysaccharide, lipoteichoic acid, *Yersinia pseudotuberculosis* YopJ protein, and protein expressed by the *Salmonella typhimurium* SPI2 locus.

15. (original) The method of Claim 6, wherein said macrophage cells are contacted with one or more of dsRNA and virus prior to contacting with a bacterium.

16. (currently amended) The method of ~~claim 13~~ Claim 15, wherein said virus comprises *Influenza virus*.

17. (original) A method of treating a microbial infection in a cell, comprising:

a) providing:

i) a cell with one or more symptoms of a microbial infection and

ii) a formulation comprising a Protein Kinase R inhibitor; and

b) administering said formulation to said cell under conditions such that said one or more symptoms of a microbial infection are reduced.

18. (original) The method of Claim 17, wherein said cell has a microbial infection associated with one or more symptoms of a viral infection.

19. (original) The method of Claim 17, wherein said microbe is a bacterium.

20. (currently amended) The method of Claim 19, wherein said bacterium is selected from ~~a group comprising~~ the group consisting of *Bacillus species*, *Yersinia species*, *Salmonella species*, *Shigella species*, *Streptococcus species* and *Haemophilus species*.

21. (currently amended) The method of Claim 18, wherein said virus is selected from a ~~group comprising~~ the group consisting of *Influenzavirus A*, *Influenzavirus B*, and *Influenzavirus C*.

22. (original) The method of Claim 17, wherein said infection is a multiple infection.

23. (original) The method of Claim 22, wherein said multiple infection comprises a bacteria infection and a virus infection.

24. (canceled).

25. (currently amended) The method of Claim 17, wherein said cell is in a human patient.

26. (currently amended) The method of Claim ~~25, wherein said patient comprises one or more of an animal and a human~~ 17, wherein said cell is in a nonhuman animal patient.

26. (canceled).

27. (original) A method of treating a microbial infection in a patient, comprising:

a) providing:

i) a patient with one or more symptoms of a microbial infection and

ii) a formulation comprising a Protein Kinase R inhibitor; and

b) administering said formulation to said patient under conditions such that said one or more symptoms of a microbial infection are reduced.

28. (original) The method of Claim 27, wherein said patient has a microbial infection associated with one or more symptoms of a viral infection.

29. (original) The method of Claim 18, wherein said infection is a bacterial infection.

30. (currently amended) The method of Claim 29, wherein said bacterium is selected from ~~a group comprising~~ the group consisting of *Bacillus species*, *Yersinia species*, *Salmonella species*, *Shigella species*, *Streptococcus species* and *Haemophilus species*.

31. (currently amended) The method of Claim 28, wherein said virus is selected from a ~~group comprising~~ the group consisting of *Influenzavirus A*, *Influenzavirus B*, and *Influenzavirus C*.

32. (original) The method of Claim 27, wherein said infection is a multiple infection.

33. (original) The method of Claim 32, wherein said multiple infection comprises a bacteria infection and a virus infection.

34. (canceled).